Combination of an oral H2S donor to dapagliflozin provides additional therapeutic benefit in a cardiorenal model of heart failure with preserved ejection fraction (HFpEF)

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression Heart Failure ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by